Literature DB >> 11574778

Expression of p57/Kip2 protein in hepatocellular carcinoma.

Y Ito1, T Takeda, M Sakon, M Tsujimoto, M Monden, N Matsuura.   

Abstract

Evaluation of the biological character of carcinomas requires understanding of cell cycle regulators. In the present study, we investigated the expression of p57 (Kip2) in 90 hepatocellular carcinomas and 66 noncancerous lesions. The average p57 labeling index in noncancerous lesions was 72.3 +/- 19.7. The labeling index significantly decreased (p < 0.0001) in hepatocellular carcinoma (54.9 +/- 19.7). It was significantly lower in hepatocellular carcinoma cases with high biological aggressiveness such as advanced stage (p = 0.0041), poor differentiation (p < 0.0001), larger size (p = 0.0400), portal invasion (p < 0.0001), satellite tumor (p = 0.0023), high proliferating activity (p = 0.0002) and cyclin D(1) overexpression (p = 0.0416). Furthermore, cases with low p57 expression showed worse outcomes for disease-free survival in univariate analysis (p = 0.0235), although p57 expression could not be recognized as an independent prognostic factor. These findings suggest that p57 contributes to the downregulation of cell proliferation and to the progression of hepatocellular carcinoma. Copyright 2001 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11574778     DOI: 10.1159/000055378

Source DB:  PubMed          Journal:  Oncology        ISSN: 0030-2414            Impact factor:   2.935


  16 in total

1.  MiR-222 overexpression promotes proliferation of human hepatocellular carcinoma HepG2 cells by downregulating p27.

Authors:  Yue-Feng Yang; Fei Wang; Jun-Jie Xiao; Yang Song; Ying-Ying Zhao; Yan Cao; Yi-Hua Bei; Chang-Qing Yang
Journal:  Int J Clin Exp Med       Date:  2014-04-15

2.  Dietary factors, genetic and epigenetic influences in colorectal cancer.

Authors:  M L Pellegrini; P Argibay; D E Gomez
Journal:  Exp Ther Med       Date:  2010-03-01       Impact factor: 2.447

3.  Stem cell associated genes working with one miRNA cluster have different clinic pathologic values in gastric cancer.

Authors:  Qiong Wu; Zhiping Yang; Sijun Hu; Tao Su; Yanxin An; Zhiyong Zhang; Yongzhan Nie; Xin Wang; Yongquan Shi; Daiming Fan
Journal:  Pathol Oncol Res       Date:  2011-05-10       Impact factor: 3.201

4.  Expression of cell cycle regulator p57kip2, cyclinE protein and proliferating cell nuclear antigen in human pancreatic cancer: an immunohistochemical study.

Authors:  Hui Yue; Hui-Yong Jiang
Journal:  World J Gastroenterol       Date:  2005-08-28       Impact factor: 5.742

5.  Expression of p57kip2, Rb protein and PCNA and their relationships with clinicopathology in human pancreatic cancer.

Authors:  Hui Yue; Yan-Li Na; Xin-Li Feng; Shu-Ren Ma; Fu-Lin Song; Bo Yang
Journal:  World J Gastroenterol       Date:  2003-02       Impact factor: 5.742

6.  Inducible expression of p57KIP2 inhibits glioma cell motility and invasion.

Authors:  K Sakai; A Peraud; T Mainprize; J Nakayama; A Tsugu; K Hongo; S Kobayashi; James T Rutka
Journal:  J Neurooncol       Date:  2004-07       Impact factor: 4.130

7.  Functional analysis of the Aurora Kinase A Ile31 allelic variant in human prostate.

Authors:  Noa Matarasso; Anat Bar-Shira; Uri Rozovski; Serena Rosner; Avi Orr-Urtreger
Journal:  Neoplasia       Date:  2007-09       Impact factor: 5.715

Review 8.  MicroRNAs in liver cancer: a model for investigating pathogenesis and novel therapeutic approaches.

Authors:  E Callegari; L Gramantieri; M Domenicali; L D'Abundo; S Sabbioni; M Negrini
Journal:  Cell Death Differ       Date:  2014-09-05       Impact factor: 15.828

9.  p57(KIP2) control of actin cytoskeleton dynamics is responsible for its mitochondrial pro-apoptotic effect.

Authors:  E Kavanagh; P Vlachos; V Emourgeon; J Rodhe; B Joseph
Journal:  Cell Death Dis       Date:  2012-05-17       Impact factor: 8.469

10.  Expression of p15INK⁴b and p57KIP² and relationship with clinicopathological features and prognosis in patients with vulvar squamous cell carcinoma.

Authors:  Ruth Holm; Mette Førsund; Mai T Nguyen; Jahn M Nesland; Claes G Trope
Journal:  PLoS One       Date:  2013-04-08       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.